Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
about
Adverse effects of biologics: a network meta-analysis and Cochrane overviewThe future of biologic agents in the treatment of Sjögren's syndromeRecent advances in primary Sjogren's syndromeResponse to peripheral immune stimulation within the brain: magnetic resonance imaging perspective of treatment successImmune-regulatory mechanisms in systemic autoimmune and rheumatic diseasesTreatment of primary Sjögren syndrome.High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial.Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatmentEULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndromeEffect of inflammation on lacrimal gland function.Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndromeCytokines in Sjogren's syndrome: potential therapeutic targets.B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndromePredominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome.Primary Sjögren's syndrome: new clinical and therapeutic conceptsLamivudine is not effective in primary Sjögren's syndrome.Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.The utility of tumour necrosis factor blockade in orphan diseases.Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.Treating Sjögren's Syndrome: Insights for the ClinicianLow-intensity pulsed ultrasound rescues insufficient salivary secretion in autoimmune sialadenitisGene therapeutics in Sjögren's syndrome.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Progress and regression within primary Sjögren's syndrome.Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's syndrome: a randomized, double-blind, placebo controlled cross-over study.Role of dendritic cells in Sjögren's syndrome.A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response.Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic sourceMonitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesSjögren's syndrome--a plethora of clinical and immunological phenotypes with a complex genetic background.T Cell-Associated Cytokines in the Pathogenesis of Sjögren's SyndromeInfliximab in dermatological treatment: beyond psoriasis.
P2860
Q24234197-FBB15D01-C0BC-4B2E-BBC8-9C45C47104FEQ24681044-8C3AAF29-01C9-4C1D-BD7C-8BA4AB291BABQ26747049-369400A4-A7C9-475A-8DA6-E1E581583314Q26782095-F198E1F8-BD6B-46DA-A9DE-371AD473375CQ26823714-D5B431B0-6EBC-4E80-984F-C3B2292551D1Q30249011-DC4A770E-A3AB-4532-9446-C17B69397190Q30372606-8C03CB3E-6526-45AB-8C11-D2F6A09CDABCQ30948155-FFD031AE-22BB-4174-AB89-6939A53910C0Q33873657-F70BE1A9-55FF-4265-B886-CDE31A50A528Q34117422-4C086602-7863-432A-ACB0-B4BF78009433Q34338027-63A4284B-5A9D-4B0B-B626-482B3EBA0643Q34413324-E5D350BD-341F-4C68-A8C8-6B31E58FA3E6Q34479625-9AF23D9B-83F6-4AEA-BBD4-27A06E0C94A6Q34601660-6AEFD2F2-E564-479C-910A-2E1316A486EFQ34896699-11283B0D-F988-47CE-8B17-0150027D76CFQ35554428-F57287C9-DC82-4A91-8080-B0F3630326EDQ35555323-49AA53C3-C040-4238-A222-2F1ECE35CAFFQ35556009-82753CB0-4A90-419D-AF99-E3B9AFCF0F94Q35579352-888E3CE0-A8D8-415E-AF12-10D32771F130Q35579517-5C8EE0F5-7581-4667-8446-A67B055D4D64Q35617617-4E41995C-2876-4E5E-BB7C-EE647B586007Q35638200-59174E9D-686E-49D8-BBF0-645EFAD64648Q35638252-E1531BED-7187-42CF-8553-FB706507F02EQ35774612-0358A318-C8A8-4E13-B70E-5E81B41E7A63Q35857131-BD9F4602-7DD1-476C-9D29-B29707C58A89Q35915996-19FB00FB-6563-4E0E-9E6F-2449C0B59475Q35953478-54C88977-13E3-4595-9B71-AD321F179B54Q36056942-DC8CF5FC-10C0-4FA5-B031-F06E13C3AAEAQ36131422-0503EF2C-9523-45B9-BA08-FDBFB8ED85FEQ36161211-F870CD01-9AD0-407C-9137-C34E4C1DC383Q36171750-15602B32-FCD6-4DF9-92A1-2E28E90B3B7AQ36391445-CE279D4E-CC4E-444D-8FD8-92B6DD90C037Q36449495-A679A681-7C8B-4739-A83D-199D9DA49D38Q36570670-AD8C96D1-FB44-4918-AE66-CE09BE9A0F5DQ36654727-6EDD7EFA-69EF-45C4-945B-B7243C9206AFQ36710557-3B0FEC20-11B7-4E7C-950D-34D6BCC0E8E3Q36724093-2DAEFDE8-1A66-4853-A930-FE4F84D055D9Q36951063-35CD45BE-CE75-4EDF-88E8-F534A073D8ECQ36957148-CE1A85EF-C2B2-4107-BB28-96F55D2C6B25Q37032659-04433E35-4085-4ABE-8B79-E537DBF9F1E6
P2860
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@en
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@nl
type
label
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@en
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@nl
prefLabel
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@en
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@nl
P2093
P2860
P356
P1476
Inefficacy of infliximab in pr ...... y Sjögren's Syndrome (TRIPSS).
@en
P2093
Aleth Perdriger
Anne Janin
Bernard Combe
Bernard Sauvezie
Eric Hachulla
Gabriel Baron
Gilles Hayem
Jean Sibilia
Joelle Goetz
Serge Steinfeld
P2860
P304
P356
10.1002/ART.20146
P577
2004-04-01T00:00:00Z